Herbert Kim Lyerly
About Herbert Kim Lyerly
Herbert Kim Lyerly is a co-founder of Replicate Bioscience, Inc. and serves on the Board of Directors at OncoSec, while holding a professorship at Duke University School of Medicine, where he specializes in cancer research and immunology.
Work at Replicate Bioscience
Herbert Kim Lyerly serves as Co-Founder at Replicate Bioscience, Inc., a position he has held since 2020. In this role, he focuses on innovative approaches to combat drug-resistant cancer mutations through the use of srRNA technology. His involvement aims to enhance treatment options for patients facing challenges with conventional therapies.
Current Roles and Responsibilities
In addition to his role at Replicate Bioscience, Lyerly is a member of the Board of Directors at OncoSec, where he has contributed since 2020. He also holds significant academic positions at Duke University School of Medicine, serving as the George Barth Gellar Professor of Cancer Research since 2004 and as a Professor in the Departments of Surgery, Pathology, and Immunology since 1990.
Education and Expertise
Lyerly's educational background includes a Doctor of Medicine (MD) degree from the University of California, Los Angeles, completed between 1980 and 1983. He furthered his studies in Molecular Virology and Immunology at Duke University School of Medicine, where he was a Post-doctoral Fellow from 1985 to 1987. He also holds a Bachelor of Science (BS) in Biomedical Sciences from the University of California, Riverside, earned from 1976 to 1980.
Background
Herbert Kim Lyerly has a long-standing career in cancer research and immunology, with over three decades of experience at Duke University School of Medicine. His research interests include the mechanisms of cancer resistance and the development of novel therapeutic strategies to improve patient outcomes.
Achievements in Cancer Research
Lyerly has made significant contributions to the field of cancer research through his academic and professional roles. His work focuses on understanding cancer biology and developing innovative solutions to address drug resistance in cancer treatment, particularly through the application of srRNA technology.